Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS Referee #1 (Remarks to the Author):
The manuscript contributes evidence that GSMs can directly bind to components of the gammasecretase complex and is thereby an important contribution to mechanistically understand Abeta generation. However, the paper is suffering form a few setbacks. The analysis of GSM-1 in figure 1 which fails to show effects on longer Abeta forms (45, 46) is a novel finding but rather unrelated to the main topic of the manuscript. In figure 3A , lane UV-, GSM binding to presenilin seems to be rather unspecific. Quality of Western blots shown in In figure 3B is rather low. This reviewer does not understand data shown in figure 7 and conclusions drawn from the results shown. In general, the specificity of binding has ben investigated by just one approach. Additional experiments using alternative methods are required to support the conclusion that GSM-1 specifically binds to PS1 TMS1.
Referee #2 (Remarks to the Author):
In this manuscript, Ohki et al elegantly elucidate the action mechanism of GSM-1, a potent gsecretase modulator (GSM), using an integrated approach of chemistry and biology. Although various GSMs have been developed, their mechanism in modulating γ-secretase specificity has been controversial; it is whether these GSMs bind to Enzyme, substrates or both. This study developed PAL based GSM1 and identified its binding protein. They have demonstrated that GSM-1 directly interacts with the TM1 of PS1-NTF, which leads to an allosteric regulation of g-secretase that alters the production of Ab42 and Ab38. This study provides convincing evidence that these GSMs directly target gamma-secretase, rather than the APP substrate, which resolves a key issue that has recently confounded researchers in the field of g-secretase modulation. Therefore, this work represents a significant progress in this field and would be an excellent article in the EMBO Journal if these issues can be addressed.
1. A wide range of concentrations of GSM-1 and its analogs (up to 241 uM) has been used for this study. Authors should provide a justification why these concentrations were chosen. For example: a) In Fig 4, 240 .9 uM of GSM-1 was used for competition studies. It appeared that GSM-1 virtually blocked all tested PAL ligands. Is this compound still soluble under this assay condition? Could this compound non-specifically precipitate proteins? A titration of GSM-1 would help clarify this point; b) In Fig 4a and d , why higher concentrations (up to10 uM) of compounds are not used for these assays?
2. This study claims the GSM-1 PAL labels PS1-FL, an inactive form of g-secretase. To support this claim, they should show that the band can be detected by both PS1-NTF and -CTF (in supp Fig 5) . Alternatively, this band could be a dimer of PS1-NTF.
3. An earlier study (Uemura et al, 2010) indicated that interaction of GSMs to g-secretase requires a binding of substrate to the docking site of enzyme. Is there any difference for GSM-1 BpB labeling in the presence and absence of APP or Notch substrates?
4. In Fig 6 if 11 (4.8 uM) 3 Can the labeling of SPP by GSM-1-BpB be blocked by SPP inhibitor? 4 A detailed description of results and figure legends would better communicate this work with EMBO readers if the page limit allows.
Referee #3 (Remarks to the Author):
The target and mechanism of gamma-secretase modulators (GSMs) that specifically lower A-beta42 production are of keen interest to the field, as understanding such issues may suggest how to improve on these potential Alzheimer therapeutic agents. In elegant experiments, Ohki and colleagues have generated photoaffinity probes of one such class of GSMs, phenylpiperidines, and demonstrated that transmembrane domain 1 of PS1 is the target. Some evidence is provided that binding of these GSMs leads to allosteric modulation of the gamma-secretase active site and initial substrate binding site. In general, this study is well designed, the experiments carefully executed, the data appropriately analyzed and interpretted, and the manuscript well written. However, several important issues require attention as noted below.
(1) In Fig 4, it seems odd that GSM-1 can reduce labeling of PS1 by affinity probes of active site compound L-685,458, initial binding site inhibitor Peptide 11, and the "transit path" binding inhibitor Compound E, but that these compounds do not affect PS1 labeling by the GSM-1 affinity probe. Often allostery can work both ways. Perhaps the competition experiments are not run under equivalent conditions? The figure legend states that for the competition, compounds were added at 10X their IC50 values. However, it is unclear how the concentrations of the photoaffinity probes compares to their IC50 values. For a fair competition, the photoaffinity probes should likewise be tested at the same fold concentration above their IC50 values.
(2) For the FLIM data in Table 1 , it is unclear whether the purported differences seen with GSM-1 and MS-1017 compared to DMSO control are statistically significant and, if so, at what level of confidence.
(3) In Fig 7a, the inhibition of SCAM labeling of M84C by GSM-1 and NS-1017 is difficult to appreciate. While there may be some slight reduction compared to DMSO control, it is subtle. This technique requires more robust inhibition of labeling to be confident that it is real. The same can be said about the inhibition of SCAM labeling at K80C by NS-1017. As these results provide the basis for the mechanistic interpretations mentioned in the text and depicted in Fig. 7C , it is important that more robust inhibition be demonstrated.
(4) Page 16, near bottom: the speculation that A-beta42-lowering GSMs affect the generation of Abeta42 from A-beta45 does not seem consistent with the results shown in this manuscript. Levels of A-beta45 do not change, while A-beta42 levels decrease and A-beta38 levels increase. Therefore, it seems that these GSMs are increasing the formation of A-beta38 from A-beta42. Response to the comments by referees
Reviewer #1 1) Effects on longer Abeta species.
The analysis of GSM-1 in figure 1 which fails to show effects on longer Abeta forms (45, 46) is a novel finding but rather unrelated to the main topic of the manuscript.
In addition to the identification of the molecular target, the other aim of our study was to gain more insights into the mechanism of action of the phenylpiperidine-type GSM, which specifically affects Abeta42 production. To date, no information has been available in the literature on the effect of GSM-1 on long Abeta species, while successive cleavage model of the gamma-secretase postulated by Dr. Ihara's group is widely supported and prevailing. Thus, we believe the data regarding the effects of GSM-1 on longer Abeta is important and would like to include it in our manuscript.
2) Specific binding of GSM-1.
In figure 3A , lane UV-, GSM binding to presenilin seems to be rather unspecific. Quality of Western blots shown in figure 3B is rather low. We have carefully repeated the photoaffinity labeling experiment by GSM-1-BpB using brain microsomes, and constantly observed a more specific labeling of PS1 NTF, which we present as the new Fig. 3a . Similarly, we were able to obtain Western blots of biontinylated PS1 NTF of higher specificity by concentrating the labeled proteins by immunoprecipitation, which we include as the new Fig. 3b . Altogether, we believe we were able to provide convincing data on the specificity of the binding of GSM-1 to PS1 NTF.
3) This reviewer does not understand data shown in figure 7 and conclusions drawn from the results shown.
We are sorry for the lack of clarity in the presentation and interpretation of the data in figure 7. By SCAM, in which the hydrophilicity of each amino acid residue is assessed by the biotinylation efficiency of mutated cysteine at the same position, we previously showed that the cytosolic side of TMD1 directly faces the hydrophilic pore in the lipid bilayer; furthermore, competition of SCAM labeling by a transition-state analogue gamma-secretase inhibitor suggested that TMD1 takes part in the formation of the catalytic site (Takagi et al, J Neurosci 2010). In our present data shown in Fig.  7 , SCAM, combined with competition, revealed that the hydrophilicity of K80 and M84 located at this region (=N-terminal, cytosolic side of TMD1) is affected by GSM-1 (Fig. 7a) . However, chimeric analysis suggested that the GSM-1 binding domain is located within the hydrophobic side of TMD1, which is located in the C-terminal (luminal side) flanking region of the hydrophilic portion ( Supplementary Fig. 10 ). Taken together with the results of the FLIM experiment, we speculated that GSM-1 and related compounds caused conformational changes of the N-terminal, cytosolic portion, by binding to the C-terminal, luminal side of the TMD1. We tried to correctly describe our interpretations at the highest possible clarity, by adding a few sentences and modifying the Fig. 7 (page 15).
4) Alternative method to prove direct binding of GSM-1.
In general, the specificity of binding has been investigated by just one approach. Additional experiments using alternative methods are required to support the conclusion that GSM-1 specifically binds to PS1 TMS1. We fully appreciate the reviewer's concern. To further substantiate the notion that GSM-1 directly binds to TMD1 of PS1, we have tested the binding of GSM-1-BpB to purified recombinant proteins encompassing different portions of the N-terminal region of PS1 (GST, GST-PS1 2-65 = N-terminal cytoplasmic portion, and GST-PS1 1-110 including TMD1 (78-100), whose expression and purity are shown in Supplementary Fig. 9 . PAL experiments on these recombinant proteins unequivocally showed that GSM-1-BpB selectively binds to GST-PS1 1-110 (Fig. 6h) . We believe this result provides further support to the conclusion that GSM-1 directly binds to TMD1 of PS1.
Reviewer #2 In this present study, we did not see any competition against the GSM-1-BpB labeling in the presence of 1 or 10 microM of GSM-1. However, we did observe a decreased labeling by GSM-1-BpB in the presence of 100 mM GSM-1. Thus, we have chosen 241 mM of GSM-1, a 10-fold higher concentration of its IC 50 (i.e., 24.09 microM), as a competitor for photoaffinity labeling, in a similar manner to that in labeling competition experiments using GSI-based photoprobes throughout this study. We also confirmed that GSM-1 was soluble at 241 mM. To further clarify the point a) above, we performed a cross competition experiment using DAP-BpB, a derivative of a gamma-secretase inhibitor DAPT, which selectively labeled PS1 CTF (Morohashi et al., JBC 2006) , and confirmed that labeling of PS1-CTF was not affected by preincubation with GSM-1 at 241 mM. Thus, GSM-1 did not induce nonspecific protein interactions at this concentration. These observations support the view that the competition by GSM-1 against labeling by photoprobes of various gamma-secretase inhibitors (i.e., L-852,646, CE-BpB3 or pep.11-Bt) is a specific event ( Supplementary Fig. 4 ). Responding to the point b) above, we also confirmed that treatment with higher concentrations (10 mM) of gammasecretase inhibitors (L-685,458, compound E or pep.11) did not affect the labeling of PS1 NTF by GSM-1-BpB ( Supplementary Fig. 3 ).
2) Detection by anti-PS1 CTF antibody.
This study claims the GSM-1 PAL labels PS1-FL, an inactive form of g-secretase. To support this claim, they should show that the band can be detected by both PS1-NTF and -CTF (in supp Fig 5). Alternatively, this band could be a dimer of PS1-NTF.
We added the result of western blot using anti-PS1 CTF antibody ( Supplementary Fig. 8 ).
3) Effect of the substrate on GSM-1 binding An earlier study (Uemura et al, 2010) 
indicated that interaction of GSMs to g-secretase requires a binding of substrate to the docking site of enzyme. Is there any difference for GSM-1 BpB labeling in the presence and absence of APP or Notch substrates?
This is an intriguing point. We have carried out an additional experiment and found that the labeling of PS1 NTF by GSM-1-BpB was not affected upon overexpression of APP-based substrates. Moreover, pretreatment with pep.11, a mimetic of the gamma-secretase substrate that inhibits both APP-and Notch-cleavage, did not alter the GSM-1-BpB labeling. These results indicate that GSM-1 binding to PS1 NTF is independent of substrate binding in our experimental paradigm.
4) IgG chains in PAL experiment
In Fig 6 if 
Can the labeling of SPP by GSM-1-BpB be blocked by SPP inhibitor?
We observed that pretreatment with 100 mM of (Z-LL) 2 -ketone did not affect labeling of SPP by GSM-1-BpB ( Supplementary Fig. 2 ) 4 A detailed description of results and figure legends would better communicate this work with EMBO readers if the page limit allows. We tried to supplement the detailed descriptions in the main text to improve communication to the readers.
Reviewer #3 1) Concentrations of the compounds used in the competition experiments.
In Fig 4, We completely agree with the reviewer's concern. Now we described the concentrations of IC 50 s of the compounds for Abeta42 production in the main text. We performed PAL using GSIs at a significantly higher concentration (10 mM) ( Supplementary Fig. 3 ), but did not detect a competition with binding of GSM-1-BpB to PS1 NTF. Moreover, the labeling by DAP-BpB, a photoprobe derived from another "transit path" binding inhibitor DAPT, which targets PS1 CTF, was never affected by GSM-1. These data support our notion that the specific binding of GSM-1 significantly affected the structure of the GSI binding sites on PS1 NTF in an allosteric manner.
2) Results of FLIM.
For the FLIM data in Table 1 , it is unclear whether the purported differences seen with GSM-1 and MS-1017 compared to DMSO control are statistically significant and, if so, at what level of confidence.
We performed statistical analyses using student's t test on the FLIM data and confirmed the statistic significance of the difference (p<0.05), which we described in table. 1.
3) Incomplete competition by GSM-1 in SCAM.
In Fig 7a, Fig. 7C , it is important that more robust inhibition be demonstrated. SCAM is applicable not only to identify compound-binding site but to detect the specific structural changes of the target (Sato et al., 2006; 2008; Takagi et al., 2010) . Competition efficiency depends on the degree of direct steric hindrance by the compounds, or on the masking of the thiol moiety by an allosteric change. For example, L-685,458, which would occupy the catalytic site, significantly decreased the biotinylation of residues adjacent to the catalytic aspartates (Sato et al., J Neurosci 2006) . Indeed, the effect of GSM-1 was subtle, as the reviewer pointed out; however, the decrease in labeling of M84C and K80C was quite constantly observed (in three independent experiments). We have previously shown that the cytoplasmic region of TMD1 takes part in the formation of the catalytic pore structure and is directly targeted by L-685,458 (Takagi et al., J Neurosci 2010) . In this study, the results of competition experiments suggest that binding of GSM-1 caused structural changes in the binding site of L-685,458 (Fig. 4) . Taken together, we suggest that the allosteric action of GSM-1 binding on the catalytic pore structure would explain the mechanism of action of GSM-1. Thank you for submitting your revised manuscript to the EMBO Journal. Your manuscript has now been seen by the original three referees and their comments are provided below. As you can see below, the referees appreciate the introduced changed and support publication here. I am therefore pleased to accept the paper. However, before doing so there are a few minor changes needed -see below. Once we received the revised version we will proceed with its acceptance for publication here.
Yours sincerely Editor
The revised version of the manuscript has been significantly improved. All points raised before have been addressed in a very appropriate manner.
Authors well addressed critical issues raised by this reviewer. However, there is a mino point. It is not clear how to get an IC50 of 24.09 micoM of GSM1. Please show a plot of inhibition. Again this work significantly contributes to the understanding of GSM selectivity and should be an excellent article on the mechanism of action of GSMs.
The authors have addressed all of my concerns, either in the cover letter or in the revised manuscript. My only further suggestion is that the abstract and text be altered to be consistent with the authors' acknowledgment that the Abeta42-lowering activity of GSMs is apparently due to enhancing conversion to Abeta38, not inhibition of trimming Abeta45 to Abeta42. For instance, the abstract refers to GSMs inhibiting "Abeta42-generating" activity, and the end of the introductory section says that GSMs "modulate production of Abeta42". These and any other parts of the manuscript that refer to GSMs affecting Abeta42 generation or production should be changed to say that GSMs enhance proteolysis of Abeta42 by gamma-secretase to Abeta38.
